专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明公开

EP2327800A1 NON-SMALL CELL LUNG CANCER DETECTION MARKER, DETECTION METHOD THEREOF, RELATED REAGENT KIT AND BIOCHIP 有权
标题翻译：检测标记用于非小细胞肺癌，检测方法，试剂盒中有连接与生物芯片研究
公开(公告)号：EP2327800A1
公开(公告)日：2011-06-01
申请号：EP09832811.5
申请日：2009-12-14
申请人： Micromedmark Biotech Co., Ltd
发明人： ZHANG, Chenyu , ZENG, Ke , ZHANG, Junfeng , BA, Yi , CHEN, Xi , LI, Haijin
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , C12Q2600/178
摘要： The present invention provides non-small cell lung cancer markers and the use thereof. The non-small cell lung cancer markers in the present invention include at least one of the 26 selected detectable mature microRNAs existing stably in human serum or plasma. The invention also provides a probe combination, kit and biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting microRNAs in the serum of lung cancer patients. By detecting the variations of microRNAs in the serum of lung cancer patients, the disease can be diagnosed in vitro; the progression course of the disease can be predicted; the occurrence of complications, the rate of relapse and the prognosis of the disease can be monitored; the drug efficacy and therapeutic effects can be analyzed. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of the low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases, all of which make it an effective means for diagnosing diseases at an early stage.
摘要翻译：本发明提供的非小细胞肺癌标记物及其用途。在本发明中的非小细胞肺癌标记物包括人血清或血浆中稳定地存在于26个选择检测的成熟微小RNA中的至少一种。因此，本发明提供了用于检测所述非小细胞肺癌标记物的测试组合，试剂盒和生物芯片。本发明进一步提供用于肺癌患者的血清中检测的miRNA的方法。通过检测肺癌患者的血清中微RNA的变型中，所述疾病可以诊断在体外; 疾病病程的进展可以预测; 并发症的发生，复发率和疾病的预后可以监测; 药效和治疗效果进行分析。在本发明的方法能够广泛光谱检测，灵敏度高，成本低，方便样品获取和保存。该方法可以在疾病的普查得到应用，解决了低特异性和灵敏性与以前的单一标志物遇到的问题，并显着增大的疾病的临床检出率，所有这些都使其以有效的手段，在早期诊断疾病阶段。

IPRDB

热门服务

关于我们

友情链接

联系方式